18:13 , Oct 12, 2018 |  BC Week In Review  |  Company News

Otsuka, Proteus to develop additional digital medicine systems

Proteus Digital Health Inc. (Redwood City, Calif.) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) expanded their collaboration to develop and commercialize additional digital medicines over the next five years. Otsuka paid Proteus $88 million in...
05:06 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

FDA approves Abilify tablets with ingestible sensor

FDA approved Abilify MyCite, which combines the antipsychotic Abilify aripiprazole from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) with an ingestible sensor from Proteus Digital Health Inc. (Redwood City, Calif.) in a single tablet to digitally...
00:01 , Nov 15, 2017 |  BC Extra  |  Company News

FDA approves Abilify tablets with ingestible sensor

Late Monday, FDA approved Abilify MyCite, which combines the antipsychotic Abilify aripiprazole from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) with an ingestible sensor from Proteus Digital Health Inc. (Redwood City, Calif.) in a single tablet...
01:31 , Sep 2, 2017 |  BioCentury  |  Strategy

Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
16:27 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

FDA approves Abilify for bipolar disorder

H. Lundbeck A/S (CSE:LUN) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA approved an sNDA for once-monthly Abilify Maintena aripiprazole to treat bipolar I disorder. Abilify Maintena is already approved to treat schizophrenia. The...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
18:43 , May 26, 2017 |  BC Week In Review  |  Clinical News

FDA again reviewing Abilify with Proteus' sensor

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Proteus Digital Health Inc. (Redwood City, Calif.) said FDA accepted for review a resubmitted NDA for antipsychotic Abilify aripiprazole with an ingestible sensor from Proteus in a single...
22:23 , May 23, 2017 |  BC Extra  |  Clinical News

FDA again reviewing Abilify with Proteus' sensor

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Proteus Digital Health Inc. (Redwood City, Calif.) said FDA has accepted for review a resubmitted NDA for antipsychotic Abilify aripiprazole with an ingestible sensor from Proteus in a...
00:29 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

Abilify Maintena regulatory update

H. Lundbeck and Otsuka said FDA accepted for review an sNDA for once-monthly Abilify Maintena aripiprazole to treat bipolar I disorder. The PDUFA date is July 28, 2017. Abilify Maintena is approved to treat schizophrenia....
02:08 , Nov 5, 2016 |  BioCentury  |  Finance

Craving Biohaven

Biohaven Pharmaceutical Holding Co. Ltd. raised a tranched $80 million private round on its management team’s track record of bringing neurology compounds through the clinic, and the range of both Orphan and common indications the...